35: High BAFF and BCR-activated B Cells in Patients with Progressive Chronic Graft Versus Host Disease After Rituximab Treatment
Year: 2008
Type: article
Abstract: We recently showed that high levels of B cell Activating Factor (BAFF) after allogeneic hematopoietic stem cell transplantation (HSCT) are associated with the development of chronic graft versus host disease (cGVHD). Clinical responses observed after treatment with rituximab (anti-CD20) also suggest a role for B cells in the immune pathology of cGVHD, but the effect of rituximab on BAFF levels and B cell repertoire in patients with cGVHD is unknown. In patients with autoimmune disease treated with rituximab, BAFF levels are elevated for 1–2 months after B cell depletion.
Institutions: Dana-Farber Cancer Institute, Harvard University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2155087150